ŌURA, the smart ring maker that helped turn nightly sleep scores into a mainstream habit, postponed its Nasdaq initial public offering on Tuesday, the day its shares were expected to be priced. The company cited uncertainty in the IPO market, but reporting on investor pushback points to a harder question: how public markets will value consumer health wearables that now describe themselves as AI platforms.
HotSpot Take
ŌURA postponed its planned Nasdaq IPO on September 29, 2026, citing IPO market uncertainty despite what it called strong demand. The offering of 50 million shares at $40 to $44 would have raised up to $2.2 billion, with 73% of the shares coming from existing stockholders. Bloomberg reports that some prospective investors balked at the valuation and that share mix. ŌURA says it is profitable, now has 5.7 million paid members, and expects 90% revenue growth in fiscal 2026. No new date has been set.
A Postponement Without a Profit Warning
The announcement came just over a week after ŌURA formally launched the offering on September 21. In its press release announcing the postponement, the company said the business has “further strengthened” since the process began. According to the company, consumer response to Oura Ring 5 has been “exceptionally strong,” paid membership has reached 5.7 million, and fiscal 2026 revenue is expected to grow 90 percent year over year.
“We aim to deliver an extraordinary IPO for our employees and investors and we have the luxury of choosing our moment.” — Tom Hale, CEO, ŌURA
“Our mission is to empower people to live healthier, longer, and an IPO is just one step in our journey,” said Tom Hale, CEO of ŌURA. “We aim to deliver an extraordinary IPO for our employees and investors and we have the luxury of choosing our moment.”
The financials in the company’s S-1 registration statement support the claim of a business that is not in distress. Revenue for the nine months ended June 30, 2026, reached $1.21 billion, up 74% from the prior-year period, with net income of $60.8 million. ŌURA reported roughly $372 million in cash at the end of June.
What Investors Reportedly Pushed Back On
The company’s statement did not explain what “uncertainty” meant. Bloomberg reported, citing people familiar with the matter, that some investors approached about the deal declined to participate over concerns including ŌURA’s target valuation and the portion of the offering made up of existing shares. Of the 50 million shares offered, ŌURA itself was selling 13.5 million; existing stockholders were selling the remaining 36.5 million, and the company would not receive proceeds from those sales.
That structure matters to buyers. When most of an offering comes from insiders cashing out rather than the company raising capital, investors tend to ask whether the sellers remain committed to the business. TechCrunch reported that early backer Forerunner Ventures planned to sell its entire 9.3% stake, and that ŌURA intended to use most of its own proceeds to cover tax obligations tied to employee stock grants vesting at the listing.
The valuation itself had climbed quickly. According to TechCrunch, ŌURA was valued at about $5.2 billion in late 2024 and about $11 billion after a $900 million funding round last October. At the top of the proposed range, the IPO implied a fully diluted valuation of roughly $15.6 billion.
“The big concern about Oura is valuation,” Jay Ritter, director of the IPO Initiative at the University of Florida, told Yahoo Finance.
Precedent may also be weighing on buyers. Bloomberg’s reporting noted that some prospective investors pointed to the weak post-IPO performance of earlier connected health device companies, including Fitbit and Peloton, both of which eventually traded below their offering prices. The broader market is also unsettled: nuclear services firm Holtec and Bamboo Insurance both postponed offerings earlier this month, and analysts cited rising bond yields as pressure on growth-company valuations.
Hardware Revenue Behind a Platform Pitch

Oura Ring Image courtesy of Oura Health
ŌURA’s S-1 describes the company as a “health intelligence platform” built on proprietary health foundation models, domain-specific algorithms, and custom large language models that power Oura Advisor, its conversational AI companion. The filing presents that AI layer as a compounding advantage fed by nearly 42 billion hours of biometric data.
The revenue mix tells a more conventional story. Hardware generated $974 million of the $1.21 billion in nine-month revenue, about 80%. Membership revenue, at $240.5 million, carries far richer margins (TechCrunch reports an 89% gross margin) and a weighted 12-month paid member retention rate of about 85%, according to the filing. Investors were effectively being asked to pay a platform multiple for a business that still sells mostly rings.
The S-1 is also candid about risk. It lists the use of AI and machine learning, “real or perceived inaccuracies” in insights, and the company’s marketing of features as general wellness products outside active FDA medical device oversight among its risk factors. It discloses that some Oura Ring 4 units exhibited battery performance issues that raised warranty costs.
None of the reporting to date attributes the postponement to consumer distrust of ŌURA’s AI features. The documented concerns are financial: price, deal structure, and market timing.
Rivals Close In From the Wrist and the Finger
Apple announced the Apple Watch Series 12 on September 9, starting at $399, the same base price as Oura Ring 5. According to Apple’s health announcement, the new Health Sensing System enables a readiness score and higher-frequency heart rate variability, while a redesigned Health app coming later this year will offer AI-driven health and longevity insights. Readiness scoring has long been one of ŌURA’s signature features.
The regulatory contrast is notable. Apple’s hypertension notifications received FDA clearance in September 2025. ŌURA’s Blood Pressure Signals feature is marketed as a wellness capability, and the company describes its blood pressure profile study, with more than 350,000 participants, as investigational.
Pricing models differ as well. Oura Membership costs $5.99 per month, while Apple and Samsung do not require subscriptions for their smartwatches, as CNN has reported. Inside the smart ring category, Samsung, Ultrahuman, and RingConn all sell rings without a required subscription for core features, and TechCrunch linked ŌURA’s shortened Ring 5 release cycle to pressure from those rivals. Whoop, which ŌURA’s S-1 also names as a competitor, shares ŌURA’s hardware-plus-membership model. ŌURA’s counterargument rests on form factor. The company claims the finger delivers a stronger optical signal than the wrist and reports that paid members wear the ring a median of about 23 hours a day.
What the Pause Signals for Consumer Health AI
ŌURA is not a struggling company, and its postponement is not a verdict on smart rings. It is, however, the first major test of whether public investors will price a consumer wearable as an AI health platform, and the initial answer appears to be “not at this price.” For peers building similar hardware-plus-AI subscription models, including companies in AI-powered sleep coaching and metabolic health, the message from the market is that recurring revenue and clinical credibility, not AI branding, will carry the valuation.
For the 5.7 million people who wear an Oura Ring, nothing changes tomorrow. The longer question is whether consumer health wearables can earn the kind of clinical validation and trust that would let their insights move from interesting to actionable in patient care. That work happens in studies and regulatory filings, not on the Nasdaq.
— This original article was created with AI support.